Extended Data Fig. 1: Characterization of cohorts and association of TMB, PD-L1, and CD8 infiltrate with outcomes. | Nature Cancer

Extended Data Fig. 1: Characterization of cohorts and association of TMB, PD-L1, and CD8 infiltrate with outcomes.

From: Tumor ecosystem and microbiome features associated with efficacy and resistance to avelumab plus chemoradiotherapy in head and neck cancer

Extended Data Fig. 1

a. Comparable PFS outcomes are seen in the biomarker analysis cohorts relative to the full dataset. Cox proportional hazards model used to estimate hazard ratio (and 95% CI) between placebo and avelumab in subgroups with genomic data. b. Tumor mutation burden (TMB) is higher in HPV negative (median=5.37 Mut/Mb, IQR=3.95-7.23, N=272) vs. HPV positive (median=4.26 Mut/Mb, IQR=2.53-6.53, N=149) (p < 0.001; Wilcoxon-rank sum test). c. Associations between PFS, treatment, and classical biomarkers were comparable in HPV-positive and HPV-negative patients (Cox proportional hazards model and 95% CI). d. Association between PFS in placebo/CRT arm and expression of PD-L1 by tumor cells (left) vs immune cells (right). PD-L1 high vs low populations (log-rank test).

Source data

Back to article page